Floatz logo

VINCRISTINE SULFATE

MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome

Prelude TherapeuticsSmall moleculePhase 1Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome cohort.

Asset / SponsorPhaseRating
prt2527
Prelude Therapeutics
Phase 1CC
Zanubrutinib
Prelude Therapeutics
Phase 1CC

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →